The FDA reassigned Sandra Retzky from her role as director of the office that oversees orphan drug designations, an administration official confirmed to Endpoints News. Retzky’s reassignment removes a senior official responsible for orphan‑designation decisions and raises short‑term questions about continuity in a team that handles incentives and regulatory guidance for rare‑disease developers. The agency will need to communicate interim leadership and maintain predictable workflows for sponsor submissions.